Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04737876 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of BX002-A in Healthy Adults
A Phase 1 study, sponsored by BiomX.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT04737876 is a Phase 1 study that has completed, run by BiomX. The registered enrollment target is 18 participants.
The verdict
NCT04737876, a Phase 1 study, has completed, sponsored by BiomX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of study BMX-02-001 is to evaluate the safety, tolerability and feasibility of orally administered BX002-A to deliver viable bacteriophages to the gut.
Interventions
- OTHER Placebo
- BIOLOGICAL BX002-A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-10-28 |
| Est. Completion | 2020-12-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04737876
The ClinicalTrials.gov registry entry for NCT04737876 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BiomX, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04737876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04737876 about?
NCT04737876 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of BX002-A in Healthy Adults". The purpose of study BMX-02-001 is to evaluate the safety, tolerability and feasibility of orally administered BX002-A to deliver viable bacteriophages to the gut.
What is the current status of trial NCT04737876?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2020-10-28. Estimated completion is 2020-12-21.
What interventions are being tested in trial NCT04737876?
The interventions under investigation include: Placebo (OTHER), BX002-A (BIOLOGICAL).
Who is sponsoring clinical trial NCT04737876?
This trial is sponsored by BiomX, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.